---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-099343"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:57:50.332883+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Gain Therapeutics hosts KOL event highlighting emerging GT-02287 Parkinson's data

## Summary
- Virtual KOL event on Oct 14, 2025 featured Dr. Karl Kieburtz (Univ. of Rochester) and Dr. Kenneth Marek (Institute for Neurodegenerative Disorders).
- Presentation focused on biomarkers, clinical endpoints, and path to disease modification for GT-02287.
- GT-02287 is a GCase-targeting small molecule for Parkinson's disease; emerging data was contextualized.
- Slides from the event were furnished as an exhibit; no new quantitative data or financial guidance provided.

## SEC filing metadata
- accession: 0001104659-25-099343
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/0001104659-25-099343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/tm2528732d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-099343
- JSON: https://secwatch.observer/filing/0001104659-25-099343.json
- Plain text: https://secwatch.observer/filing/0001104659-25-099343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.